Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae

Journal of Infectious Diseases

Volumn 188, Issue 3, 2003, Pages 339-348

  Briles, David E ^a,f   Hollingshead, Susan K ^a   Paton, James C ^e   Ades, Edwin W ^d   Novak, Lea ^b   Van Ginkel, Frederik W ^a   Benjamin Jr , William H ^c  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c University of Alabama at Birmingham   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ALUMINUM HYDROXIDE; IMJECT ALUM; IMMUNOLOGICAL ADJUVANT; MAGNESIUM HYDROXIDE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; RECOMBINANT PNEUMOCOCCAL SURFACE ADHESIN A; RECOMBINANT PNEUMOCOCCAL SURFACE PROTEIN A; RECOMBINANT PNEUMOLYSIN; RECOMBINANT PROTEIN; UAB 055; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CONTROLLED STUDY; FEMALE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LOBAR PNEUMONIA; LUNG INFECTION; MOUSE; NONHUMAN; NOSE; PRIORITY JOURNAL; SEPSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; FOCAL INFECTION; IMMUNIZATION; LUNG; MICE; MICE, INBRED CBA; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 0042665483     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376571     Document Type: Article

References (43)

1. Shapiro ED, Berg AT, Austrian R, et al. Protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
2. Saeland E, Vidarsson G, Jonsdottir I. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb Pathog 2000; 29:81-91.
3. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
4. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-5.
5. Breiman RF. Vaccines as tools for advancing more than public health: perspectives of a former director of the National Vaccine Program office. Clin Infect Dis 2001; 32:283-8.
6. Breiman RF, Butler JC, McInnes PM. Vaccines to prevent respiratory infection: opportunities on the near and far horizon. Curr Opin Infect Dis 1999; 12:145-52.
7. Briles DE, Paton JC, Nahm MH, Swiatlo E. Immunity to Streptococcus pneumoniae. In: Cunningham M, Fujinami RS, eds. Effect of microbes on the immune system. Philadelphia: Lippincott-Raven, 2000:263-80.
8. Tuomanen E. Molecular and cellular biology of pneumococcal infection. Curr Opin Microbiol 1999; 2:35-9.
9. Briles DE, Ades E, Paton JC, et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000; 68:796-800.
10. Ogunniyi AD, Folland RL, Briles DB, Hollingshead SK, Paton JC. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000; 68:3028-33.
11. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with rPspA elicits antibodies, which passively protect mice from fatal infection with Streptococcus pneumoniae-bearing heterologous PspA. J Infect Dis 2000; 182:1694-701.
12. Wu H-Y, Nahm M, Guo Y, Russell M, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage and infection with Streptococcus pneumoniae. J Infect Dis 1997; 175:839-46.
13. McDaniel LS, Scott G, Kearney JF, Briles DE. Monoclonal antibodies against protease sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med 1984; 160:386-97.
14. Paton JC, Lock RA, Hansman DC. Effect of immunization with pneumolysin on survival time of mice challanged with Streptococcus pneumoniae. Infect Immun 1983; 40:548-52.
15. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. A strong association between capsular type and mouse virulence among human isolates of Streptococcus pneumoniae. Infect Immun 1992; 60:111-6.
16. Takashima K, Tateda K, Matsumoto T, Ilzawa J, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997; 65:257-60.
17. Briles DE, Nahm M, Schroer K, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med 1981; 153:694-705.
18. Briles DE, Forman C, Horowitz JC, et al. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 1989; 57:1457-64.
19. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944; 79:137-58.
20. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989; 57:2037-42.
21. Benton KA, Everson MP, Briles DE. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun 1995; 63:448-55.
22. Hollingshead SK, Becket RS, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000; 68:5889-900.
23. Coral MCV, Fonseca N, Castaneda E, Di Fabio JL, Hollingshead SK, Briles DE. Families of pneumococcal surface protein A (PspA) of Streptococcus pneumoniae invasive isolates recovered from Colombian children. Emerg Infect Dis 2001; 7:832-6.
24. Kerner JD, Mohr RN, et al. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 1995; 3:301-12.
25. Briles DE, Horowitz J, McDaniel LS, et al. Genetic control of susceptibility to pneumococcal infection. Curr Top Microbiol Immunol 1986; 124:103-20.
26. Balachandran P, Hollingshead SK, Paton JC, Briles DE. The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol 2001; 183:3108-16.
27. Kadioglu A, Gingles NA, Grattan K, Kerr A, Mitchell TJ, Andrew PW. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68:492-501.
28. Yother J, Briles DE. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol 1992; 174:601-9.
29. McDaniel LS, Ralph BA, McDaniel DO, Briles DE. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 1994; 17:323-37.
30. De BK, Sampson JS, Ades EW, et al. Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli. Vaccine 2000; 18:1811-21.
31. Paton JC, Lock RA, Lee C-J, et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 1991; 59:2297-304.
32. Wu H-Y, Virolainen A, Mathews B, King J, Russell M, Briles DE. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathogen 1997; 23:127-37.
33. Weiser JN. Phase variation in colony opacity by Streptococcus pneumoniae. Microb Drug Resist 1998; 4:129-35.
34. Weiser NJ, Austrian R, Sreenivasan PK, Masure HR. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 1994; 62:2582-9.
35. McDanid LS, Benjamin WH Jr, Forman C, Briles DE. Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol 1984; 133:3308-12.
36. Briles DE, Forman C, Crain M. Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun 1992; 60:1957-62.
37. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspAs can inhibit complement deposition and confer virulence to a capsular 3 serotype Streptococcus pneumoniae. Infect Immun 2003; 71:75-85.
38. Tu A-HT, Fulgham RL, McCory MA, Briles DE, Szalai AJ. Pneumococcal surface protein A (PspA) inhibits complement activation by Streptococcus pneumoniae. Infect Immun 1999; 67:4720-4.
39. Rubins JB, Charboneau D, Fashing C, et al. Distinct roles for pneumolysin's cytotoxic and complement activities in pathogenesis of pneumococcal pneumonia. Am J Respir Crit Care Med 1996; 153:1339-46.
40. Alexander JE, Berry, AM, Paton JC, Rubins JB, Andrew PW, Mitchell TJ. Amino acid changes affecting the activity of pneumolysin alter the behavior of pneumococci in pneumonia. Microb Pathog 1998; 24:167-74.
41. Paton JC, Rowan-Kelly B, Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 1984; 43:1085-7.
42. Kobzik L. The lung. In: Cotran RS, Kumar V, Collins T, eds. Robbins pathogenic basis of disease. Philadelphia: WB Saunders, 1999:717-21.
43. Gray BM, Converse GM 3rd, Dillon HC. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980; 142:923-33.